Safety and Effects of Daily 25mg Empagliflozin in Adults on Peritoneal Dialysis with Remaining Kidney Function

What this Trial Is About

The trial investigates the safety and mechanisms of SGLT2 inhibitors in people on peritoneal dialysis who still have some residual kidney function. This study addresses the need for new treatments to protect heart and kidney health in these patients, including those with and without type 2 diabetes. The research aims to understand how these drugs work in dialysis patients and guide future larger studies and treatment decisions beyond end-stage kidney disease. Participants will receive 25 mg of empagliflozin once daily by mouth for two weeks in an open-label, single-arm study. The study focuses on patients with residual kidney function undergoing peritoneal dialysis. Researchers will monitor changes in kidney function and other health markers during and shortly after the treatment period to evaluate the drugs effects and safety. During the study, participants will undergo assessments including measurements of kidney filtration rate, urine and dialysate analysis, blood pressure, body weight and composition, blood tests for HbA1c and other markers related to heart, kidney, and metabolic health. Safety will be closely monitored for complications such as infections, volume depletion, or diabetic ketoacidosis. The total participation time includes baseline and two-week follow-up evaluations, with detailed monitoring of kidney and cardiovascular responses.

meChANisms and sAfety of SGLT2 Inhibition in peRitoneal dialYsis